HansBiomed Corporation (042520) — Cash Flow-to-Debt Ratio
HansBiomed Corporation (042520) has a Cash Flow-to-Debt Ratio of 0.01x as of September 2025, meaning its operating cash flow of ₩1.21 Billion could theoretically repay 0% of its total liabilities (₩92.52 Billion) in one year. See 042520 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
HansBiomed Corporation Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for HansBiomed Corporation across 14 annual periods. Also explore 042520 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for HansBiomed Corporation (2012–2025)
Year-by-year debt coverage analysis for HansBiomed Corporation. For market capitalisation and broader financial context, see HansBiomed Corporation (042520) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.00x | ₩318.34 Million | ₩92.52 Billion | ▼ -89.3% |
| 2024 | 0.03x | ₩1.76 Billion | ₩54.59 Billion | ▲ +162.5% |
| 2023 | -0.05x | ₩-3.73 Billion | ₩72.42 Billion | ▼ -3.9% |
| 2022 | -0.05x | ₩-4.27 Billion | ₩86.05 Billion | ▲ +71.2% |
| 2021 | -0.17x | ₩-14.64 Billion | ₩84.99 Billion | ▼ -314.1% |
| 2020 | 0.08x | ₩5.75 Billion | ₩71.47 Billion | ▼ -47.8% |
| 2019 | 0.15x | ₩7.71 Billion | ₩50.03 Billion | ▼ -21.5% |
| 2018 | 0.20x | ₩5.20 Billion | ₩26.49 Billion | ▼ -7.1% |
| 2017 | 0.21x | ₩5.60 Billion | ₩26.46 Billion | ▲ +1297.7% |
| 2016 | -0.02x | ₩-316.10 Million | ₩17.90 Billion | ▼ -104.6% |
| 2015 | 0.39x | ₩3.47 Billion | ₩8.95 Billion | ▼ -7.0% |
| 2014 | 0.42x | ₩2.06 Billion | ₩4.95 Billion | ▼ -27.7% |
| 2013 | 0.58x | ₩2.33 Billion | ₩4.05 Billion | ▲ +15.5% |
| 2012 | 0.50x | ₩1.50 Billion | ₩3.01 Billion | — |